Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 5 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 8 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 5 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 8 5 W O ELECTROLYTES.
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 8.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy. Dextrose stimulates insulin release, promoting cellular uptake of amino acids.
TRAVASOL 8.5% W/O ELECTROLYTES provides amino acids for protein synthesis, serving as a source of nitrogen and essential amino acids to support anabolism and prevent catabolism in patients unable to tolerate oral or enteral nutrition.
Intravenous administration based on protein requirements: 1.0-2.0 g/kg/day amino acids, corresponding to 20-40 mL/kg/day of AMINOSYN II 5% in DEXTROSE 25%. Typical adult dose starts at 30-40 mL/hour, titrated to metabolic goals.
Intravenous infusion; 500 mL to 1 L per day, administered at a rate of 100-200 mL/hour. Dosage depends on protein and calorie requirements, typically 0.8-1.5 g/kg/day of amino acids.
None Documented
None Documented
Not applicable as a single entity; amino acids have rapid plasma clearance (t1/2 of minutes to hours) and dextrose is rapidly cleared (t1/2 ~1-2 hours). Clinical context: Continuous infusion maintains steady state.
Not applicable as a single value; amino acids have variable half-lives (minutes to hours) depending on individual metabolic demand and plasma concentration; continuous infusion achieves steady state rapidly.
Amino acids are primarily metabolized; nitrogen is excreted as urea (renal, ~85%) and ammonia (renal, ~2-5%); glucose is fully metabolized to CO2 and water (exhaled and renal); electrolytes are excreted renally. Less than 5% excreted unchanged renally.
Primarily eliminated via metabolic pathways (hepatic deamination and transamination) with nitrogenous waste excreted renally as urea; negligible biliary/fecal excretion of unchanged amino acids.
Category C
Category C
Amino Acid Solution
Amino Acid Solution